Literature DB >> 28390016

Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal".

Odette Reifsnider1, Fiona Hall2, Sonja Sorensen3, Irina Proskorovsky4, Isabelle Girod2, Jennifer Lee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28390016     DOI： 10.1007/s40273-017-0502-8

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

Review 1.  Overview of parametric survival analysis for health-economic applications.

Authors:  K Jack Ishak; Noemi Kreif; Agnes Benedict; Noemi Muszbek
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

2.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

3.  Modelling survival in hepatocellular carcinoma.

Authors:  Noemi Muszbek; Noemi Kreif; Adriana Valderrama; Agnes Benedict; Jack Ishak; Paul Ross
Journal:  Curr Med Res Opin       Date:  2012-06-26       Impact factor: 2.580

4.  Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.

Authors:  F Joulain; I Proskorovsky; C Allegra; J Tabernero; M Hoyle; S U Iqbal; E Van Cutsem
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

Review 5.  Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Authors:  Bram L T Ramaekers; Rob Riemsma; Florian Tomini; Thea van Asselt; Sohan Deshpande; Steven Duffy; Nigel Armstrong; Johan L Severens; Jos Kleijnen; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981
  5 in total
  1 in total

1.  Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".

Authors:  Bram L T Ramaekers; Rob Riemsma; Florian Tomini; Thea van Asselt; Sohan Deshpande; Steven Duffy; Nigel Armstrong; Johan L Severens; Jos Kleijnen; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2017-06       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.